Payment overview · 2025
General Payments
$213.91
2 reported records · 2 companies
Healthcare provider profile · identity verified
Mark S Gresla, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · DECATUR, IN · NPI 1467482034
Verified facts
What the public records show
CMS Open Payments records show Mark S Gresla, M.D. received $213.91 in general payments during 2025 across 2 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 52.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $112.68 | 52.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $101.23 | 47.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $213.91 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $112.68 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $101.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 693 | 108 |
| Levothyroxine Sodium | Levothyroxine Sodium | 561 | 86 |
| Gabapentin | Gabapentin | 550 | 77 |
| Furosemide | Furosemide | 469 | 79 |
| Tamsulosin Hcl | Tamsulosin Hcl | 413 | 52 |
| Eliquis | Apixaban | 367 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 320 | 54 |
| Amlodipine Besylate | Amlodipine Besylate | 289 | 57 |
| Potassium Chloride | Potassium Chloride | 284 | 56 |
| Donepezil Hcl | Donepezil Hcl | 271 | 40 |
| Metformin Hcl | Metformin Hcl | 258 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 253 | 60 |
| Lisinopril | Lisinopril | 220 | 41 |
| Sertraline Hcl | Sertraline Hcl | 216 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 208 | 29 |
| Losartan Potassium | Losartan Potassium | 207 | 34 |
| Omeprazole | Omeprazole | 206 | 37 |
| Carvedilol | Carvedilol | 198 | 31 |
| Buspirone Hcl | Buspirone Hcl | 195 | 33 |
| Memantine Hcl | Memantine Hcl | 191 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 186 | 26 |
| Famotidine | Famotidine | 174 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 168 | 36 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 161 | 18 |
| Bumetanide | Bumetanide | 152 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 152 | 43 |
| Jardiance | Empagliflozin | 150 | 21 |
| Trazodone Hcl | Trazodone Hcl | 139 | 28 |
| Tradjenta | Linagliptin | 135 | 12 |
| Levetiracetam | Levetiracetam | 130 | 13 |
| Xarelto | Rivaroxaban | 128 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 123 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 113 | 21 |
| Spironolactone | Spironolactone | 113 | 19 |
| Montelukast Sodium | Montelukast Sodium | 112 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 111 | 35 |
| Finasteride | Finasteride | 99 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 94 | 17 |
| Allopurinol | Allopurinol | 91 | 16 |
| Cephalexin | Cephalexin | 88 | 45 |
| Alendronate Sodium | Alendronate Sodium | 85 | 18 |
| Divalproex Sodium | Divalproex Sodium | 85 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 80 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 76 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 75 | 15 |
| Topiramate | Topiramate | 73 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 72 | 14 |
| Myrbetriq | Mirabegron | 72 | suppressed |
| Gemtesa | Vibegron | 71 | suppressed |
| Mirtazapine | Mirtazapine | 70 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 69 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 63 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 63 | 14 |
| Torsemide | Torsemide | 62 | 12 |
| Warfarin Sodium | Warfarin Sodium | 61 | 13 |
| Prednisone | Prednisone | 59 | 16 |
| Meloxicam | Meloxicam | 58 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | 16 |
| Latanoprost | Latanoprost | 57 | 14 |
| Midodrine Hcl | Midodrine Hcl | 57 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 54 | 13 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 54 | 20 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 53 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 53 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 47 | 18 |
| Lamotrigine | Lamotrigine | 46 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 45 | suppressed |
| Ozempic | Semaglutide | 45 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 44 | 17 |
| Amantadine | Amantadine Hcl | 44 | suppressed |
| Ezetimibe | Ezetimibe | 44 | suppressed |
| Primidone | Primidone | 44 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 43 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | suppressed |
| Baclofen | Baclofen | 42 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 42 | suppressed |
| Aripiprazole | Aripiprazole | 41 | suppressed |
| Sucralfate | Sucralfate | 41 | 11 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 38 | suppressed |
| Lovastatin | Lovastatin | 37 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Bupropion Xl | Bupropion Hcl | 36 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 36 | suppressed |
| Nystatin | Nystatin | 36 | 20 |
| Metformin Hcl Er | Metformin Hcl | 35 | suppressed |
| Risperidone | Risperidone | 35 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | suppressed |
| Celecoxib | Celecoxib | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | 11 |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 21 |
| Linzess | Linaclotide | 31 | suppressed |
| Nystop | Nystatin | 31 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Olanzapine | Olanzapine | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 29 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 25 |
| Methenamine Hippurate | Methenamine Hippurate | 29 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 29 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 28 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 26 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Water | Water For Irrigation,sterile | 26 | suppressed |
| Budesonide | Budesonide | 25 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Sodium Chloride | Sodium Chloride Irrig Solution | 24 | suppressed |
| Sotalol | Sotalol Hcl | 24 | suppressed |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 23 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 19 |
| Sevelamer Hcl | Sevelamer Hcl | 23 | suppressed |
| Letrozole | Letrozole | 22 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Brilinta | Ticagrelor | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 20 |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 21 | 11 |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Tivicay | Dolutegravir Sodium | 21 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 19 | 12 |
| Dutasteride | Dutasteride | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Metolazone | Metolazone | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 17 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 17 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 17 | 12 |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Restasis | Cyclosporine | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Entacapone | Entacapone | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | suppressed |
| Dupixent Syringe | Dupilumab | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Cefazolin Sodium | Cefazolin Sodium | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Erythromycin | Erythromycin Base | 14 | suppressed |
| Lumigan | Bimatoprost | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 14 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 14 | suppressed |
| Rexulti | Brexpiprazole | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Levetiracetam Er | Levetiracetam | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Austedo Xr | Deutetrabenazine | 12 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $213.91 · 2 records | Otsuka America Pharmaceutical, Inc. | EVENITY, REXULTI | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Otsuka America Pharmaceutical, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error